This company listing is no longer active
Eden Empire Past Earnings Performance
Past criteria checks 0/6
Eden Empire's earnings have been declining at an average annual rate of -2%, while the Pharmaceuticals industry saw earnings growing at 19.4% annually. Revenues have been growing at an average rate of 197.5% per year.
Key information
-2.0%
Earnings growth rate
15.8%
EPS growth rate
Pharmaceuticals Industry Growth | 7.3% |
Revenue growth rate | 197.5% |
Return on equity | n/a |
Net Margin | -1,716.9% |
Last Earnings Update | 30 Apr 2022 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How Eden Empire makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Apr 22 | 0 | -5 | 2 | 0 |
31 Jan 22 | 0 | -5 | 2 | 0 |
31 Oct 21 | 0 | -4 | 2 | 0 |
31 Jul 21 | 0 | -4 | 2 | 0 |
30 Apr 21 | 0 | -5 | 3 | 0 |
31 Jan 21 | 0 | -4 | 2 | 0 |
31 Oct 20 | 0 | -4 | 2 | 0 |
31 Jul 20 | 0 | -5 | 3 | 0 |
30 Apr 20 | 0 | -3 | 3 | 0 |
Quality Earnings: GA1B is currently unprofitable.
Growing Profit Margin: GA1B is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if GA1B's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare GA1B's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GA1B is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (9.4%).
Return on Equity
High ROE: GA1B's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.